Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - Accuray Incorporated (ARAY-NASDAQ)

wpe11.jpg (7184 bytes)

“If you are a patient, you should remember that Accuray’s CyberKnife is an alternative to surgery. It’s a non-invasive, painless out-patient procedure. The Cyberknife can treat inoperable tumors, and even if operable, you don’t want to cut open the patient, crack open their rib cage, and deflate their lungs in order to treat a lung tumor or invasively treat a tumor that is wrapped around the spine. It may be inoperable in that case.  Our technology offers the means to deliver high doses of radiation...” - Robert E. McNamara (ARAY) (Interview published May 30, 2008)

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE COVER ARCHIVES  |  INDEX  |  CONTACT  |  FINANCIALS |  SERVICES  | HOME PAGE


CEOCFO
-Members Login

Become A Member!



 

Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results

SUNNYVALE, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its second quarter fiscal year 2009, ending December 27, 2008, on Thursday, January 29, 2009 after the market closes.

A conference call to review the results will begin at 2:00 p.m. PST / 5:00 p.m. EST and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer, and Derek Bertocci, senior vice president and chief financial officer.

The conference call dial-in numbers are 1-866-379-2019 (USA) or 1-706-634-1525 (International), Conference ID: 80572858 In addition, a dial-up replay of the conference call will be available beginning January 29, 2009 at 5:00 p.m. PST / 8:00 p.m. EST and ending on January 31, 2009. The replay telephone number is 1-800-642-1687 (USA) or 1-706-645-9291 (International), Conference ID: 80572858.

A live webcast of the call will also be available from the Investor Relations section of the corporate Web site at http://www.accuray.com. A webcast replay can be accessed on the corporate Web site beginning Thursday, January 29, 2009 at approximately 5:00 p.m. PST / 8:00 p.m. EST. The replay will remain available until Accuray announces its results for the third quarter of fiscal 2009, ending March 28, 2009.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 150 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

SOURCE Accuray Incorporated
01/14/2009
CONTACT: Investors, Tom Rathjen, Vice President, Investor Relations, +1- 408-789-4458, trathjen@accuray.com, or Media, Stephanie Tomei, Manager, Public Relations, +1-408-789-4234, stomei@accuray.com
Web site: http://www.accuray.com/


			

			

			
 




    

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.